Optimal gadolinium dose level for magnetic resonance imaging (MRI) contrast enhancement of U87-derived tumors in athymic nude rats for the assessment of photodynamic therapy

2009 ◽  
Author(s):  
Nathan Cross ◽  
Davood Varghai ◽  
Chris A. Flask ◽  
Denise K. Feyes ◽  
Nancy L. Oleinick ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Photodynamic Therapy ◽  
Magnetic Resonance ◽  
Contrast Enhancement ◽  
Dose Level ◽  
Resonance Imaging ◽  
Mri Contrast ◽  
Nude Rats ◽  
Magnetic Resonance Imaging Mri

Biocompatible dextran-coated gadolinium-doped cerium oxide nanoparticles as MRI contrast agents with high T1 relaxivity and selective cytotoxicity to cancer cells

2021 ◽  
Author(s):  
Anton Popov ◽  
Maxim Artemovich Abakumov ◽  
Irina Savintseva ◽  
Artem Ermakov ◽  
Nelly Popova ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Cerium Oxide Nanoparticles ◽  
Oxide Nanoparticles ◽  
Resonance Imaging ◽  
Mri Contrast ◽  
Selective Cytotoxicity ◽  
Magnetic Resonance Imaging Mri

Gd-based complexes are widely used as magnetic resonance imaging (MRI) contrast agents. The safety of previously approved contrast agents is questionable and is being re-assessed. The main causes of concern...

Switchable 19F MRI polymer theranostics: towards in situ quantifiable drug release

2017 ◽  
Vol 8 (34) ◽  
pp. 5157-5166 ◽  
Author(s):  
A. V. Fuchs ◽  
A. P. Bapat ◽  
G. J. Cowin ◽  
K. J. Thurecht
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Hyperbranched Polymer ◽  
Relaxation Times ◽  
Mri Contrast Agent ◽  
Resonance Imaging ◽  
Mri Contrast ◽  
19F Mri ◽  
Magnetic Resonance Imaging Mri

A switchable polymeric 19F magnetic resonance imaging (MRI) contrast agent was synthesised whereby the transverse (T2) relaxation times increased as a therapeutic was released from a hyperbranched polymer (HBP) scaffold.

scholarly journals NIMG-33. CHANGES IN MAGNETIC RESONANCE IMAGING AFTER PROTON BOOST THERAPY FOR GLIOBLASTOMA WITH AND WITHOUT TUMOR TREATING FIELDS THERAPY

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii155-ii155
Author(s):  
Hanna Goett ◽  
Alexandra Jensen ◽  
Tobias Struffert ◽  
Eberhard Uhl ◽  
Marco Stein
Keyword(s):  
Magnetic Resonance Imaging ◽  
Radiation Therapy ◽  
Magnetic Resonance ◽  
Contrast Enhancement ◽  
Median Overall Survival ◽  
Progressive Disease ◽  
Tumor Resection ◽  
Resonance Imaging ◽  
Tumor Treating Fields ◽  
Magnetic Resonance Imaging Mri

Abstract BACKGROUND Tumor treating fields (TTFields) are an approved glioblastoma (GBM) treatment modality that demonstrated a significant improved median overall survival in newly diagnosed GBM patients. Data about morphologic changes in serial magnetic resonance imaging (MRI) for patients with a combination therapy of TTFields and proton boost therapy does not exist. METHODS Twenty-two patients were included in this study. All patients were treated with initial tumor resection followed by combined chemo- and radiation therapy. Radiation therapy was performed with 50.0 Gy photons and a proton boost with 10 Gy equivalent (Gy(RBE)). 11 patients were additionally treated with TTFields. RESULTS A new increase in contrast enhancement and/or a progress in the T2 FLAIR hyperintensity was observed in 54.5% (N=12) at 3 months and in 31.8% (N=7) at 6 months. No differences were observed between patients with and without TTFields therapy at 3 months [63.6% (N=7) vs. 45.5% (N=5); P=0.392] and at 6 months [27.3 (N=3) vs. 36.3% (N=4); P=0.647). By the RANO criteria a progressive disease (PD) was observed in 6 patients (27.3%) at 3 months and in 7 patients (31.8%) at 6 months. Pseudoprogression (PP) was observed in in 36.4% (N=8) at months and in 27.3% (N=6) at 6 months. Neither for PD at 3 months [36.4% (N=4) vs. 18.2% (N=2); P=0.338] or at 6 months [36.4% (N=4) vs. 27.3% (N=3); P=0.647), nor for PP at 3 months [45.5% (N=5) vs. 27.2% (N=3); P=0.375] or at 6 months [18.2% (N=2) vs. 36.4% (N=4); P=0.338] differences for patients with and without TTFields therapy were found. CONCLUSION Increased contrast enhancement and/or increased T2 FLAIR MRI hyperintensity after proton boost therapy are common. Furthermore, the rates for new contrast enhancement, PD, and PP after photon therapy with and without additional TTFields therapy are comparable.

Delineating Toxicity Mechanisms Associated with MRI Contrast Enhancement through a Multidimensional Toxicogenomic Profiling of Gadolinium

2022 ◽  
Author(s):  
Roger M. Pallares ◽  
Dahlia D An ◽  
Solene Hebert ◽  
David Faulkner ◽  
Alex Loguinov ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Contrast Agent ◽  
Contrast Enhancement ◽  
Clinical Settings ◽  
Resonance Imaging ◽  
Mri Contrast ◽  
Toxicity Mechanisms

Although gadolinium is widely used for magnetic resonance imaging in clinical settings, many concerns regarding its toxicity and bioaccumulation after gadolinium-based contrast agent (GBCA) administration have been raised and published...

scholarly journals Effect of Gd and Dy Concentrations in Layered Double Hydroxides on Contrast in Magnetic Resonance Imaging

Processes ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 462 ◽  
Author(s):  
Karina Nava Andrade ◽  
Gregorio Guadalupe Carbajal Arízaga ◽  
José Antonio Rivera Mayorga
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Resonance Imaging ◽  
Mri Contrast ◽  
Molar Ratios ◽  
Magnetic Resonance Imaging Mri ◽  
Double Hydroxide ◽  
Double Hydroxides

In this work, we explore the synthesis of layered double hydroxide (LDH) particles containing different molar ratios of Gd3+ and Dy3+ cations. A single crystalline phase was obtained for Zn2.0Al0.75Gd0.125Dy0.125-LDH and Zn2.0Al0.5Gd0.25Dy0.25-LDH, and their efficiency as contrast agents was evaluated by T1- and T2-weighted magnetic resonance imaging (MRI). Both GdDy-LDHs exhibited longitudinal relaxivity (r1) higher than a commercial reference. The highest contrast in the T1 mode was achieved with the Zn2.0Al0.75Gd0.125Dy0.125-LDH, which contained the lowest concentration of lanthanides; this efficiency is related to the lowest amount of carbonate anions complexing the lanthanide sites. On the contrary, the best contrast in the T2 mode was achieved with Zn2.0Al0.5Gd0.25Dy0.25-LDH. Zn2.0Al0.75Gd0.125Dy0.125-LDH and Zn2.0Al0.5Gd0.25Dy0.25-LDH presented r2/r1 ratios of 7.9 and 22.5, respectively, indicating that the inclusion of gadolinium and dysprosium into layered structures is a promising approach to the development of efficient bimodal (T1/T2) MRI contrast agents.

scholarly journals Ferritin: A Platform for MRI Contrast Agents Delivery

Inorganics ◽  
2019 ◽  
Vol 7 (3) ◽  
pp. 33 ◽  
Author(s):  
Maria Ruggiero ◽  
Diego Alberti ◽  
Valeria Bitonto ◽  
Simonetta Geninatti Crich
Keyword(s):  
Magnetic Resonance Imaging ◽  
Targeted Therapy ◽  
Magnetic Resonance ◽  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Resonance Imaging ◽  
Mri Contrast ◽  
Magnetic Resonance Imaging Mri ◽  
Accurate Imaging ◽  
Unique Surface

The search for high relaxivities and increased specificity continues to be central to the development of paramagnetic contrast agents for magnetic resonance imaging (MRI). Ferritin, due to its unique surface properties, architecture, and biocompatibility, has emerged as a natural nanocage that can potentially help to reach both these goals. This review aims to highlight recent advances in the use of ferritin as a nanoplatform for the delivery of metal-based MRI contrast agents (containing Gd3+, Mn2+, or Fe2O3) alone or in combination with active molecules used for therapeutic purposes. The collected results unequivocally show that the use of ferritin for contrast agent delivery leads to more accurate imaging of cancer cells and a significantly improved targeted therapy.

Sign in / Sign up

Export Citation Format

Share Document